Our Focus

Acute kidney injury remains a major unmet medical need, affecting millions of hospitalized patients each year and driving progression to chronic kidney disease, dialysis, and increased mortality.

Nephraxis is focused on therapeutic intervention during the recovery window after AKI, where targeted treatment has the potential to meaningfully alter long-term renal outcomes.

Our Approach

• Repurposed pharmacology with extensive human safety experience
• Mechanism-driven focus on renal recovery biology
• Designed for hospital-based and peri-procedural use
• Development strategy aligned with rapid clinical translation

Status

Nephraxis is currently selectively engaging with strategic partners, clinical collaborators, and advisors.